UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.)

		ne Registrant [Filed by a Party other than the Registrant [appropriate box:
	Conf Defin Defin	ninary Proxy Statement idential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) uitive Proxy Statement uitive Additional Materials iting Material under §240.14a-12
		Crinetics Pharmaceuticals, Inc. (Name of Registrant as Specified In Its Charter)
		(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
Pay	ment c	of Filing Fee (Check the appropriate box):
	No fe	ee required.
	Fee c	omputed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
	(1)	Title of each class of securities to which transaction applies:
	(2)	Aggregate number of securities to which transaction applies:
	(3)	Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):
	(4)	Proposed maximum aggregate value of transaction:
	(5)	Total fee paid:
	Fee p	aid previously with preliminary materials.
	Chec the p	k box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify previous filing by registration statement number, or the Form or Schedule and the date of its filing.
	(1)	Amount Previously Paid:
	(2)	Form, Schedule or Registration Statement No.:
	(3)	Filing Party:
	(4)	Date Filed:
_		



Crinetics Pharmaceuticals, Inc. Important Notice Regarding the Availability of Proxy Materials

Stockholders Meeting to be held on June 17, 2022

For Stockholders of record as of April 19, 2022

This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. This is not a ballot. You cannot use this notice to vote your shares. We encourage you to access and review all of the important information contained in the proxy materials before voting.

To view the proxy materials, and to obtain directions to attend the meeting virtually, go to: www.proxydocs.com/CRNX

To vote your proxy while visiting this site, you will need the 12 digit control number in the box below.

Under United States Securities and Exchange Commission rules, proxy materials do not have to be delivered in paper. Proxy materials can be distributed by making them available on the internet.



For a convenient way to view proxy materials and VOTE go to www.proxydocs.com/CRNX

Have the 12 digit control number located in the shaded box above available when you access the website and follow the instructions.



If you want to receive a paper or e-mail copy of the proxy material, you must request one. There is no charge to you for requesting a copy. In order to receive a paper package in time for this year's meeting, you must make this request on or before June 7, 2022.

To order paper materials, use one of the following methods.



INTERNET www.investorelections.com/CRNX

TELEPHONE (866) 648-8133



When requesting via the Internet or telephone you will need the 12 digit control number located in the shaded box above.

If requesting material by e-mail, please send a blank e-mail with the 12 digit control number (located above) in the subject line. No other requests, instructions OR other inquiries should be included with your e-mail requesting material.

Crinetics Pharmaceuticals, Inc.

Meeting Type: Annual Meeting of Stockholders

Date: Friday, June 17, 2022 Time: 8:00 AM, Pacific Time

Place: Annual Meeting to be held live via the Internet - please visit

www.proxydocs.com/CRNX for more details

You must register to attend the meeting online and/or participate at www.proxydocs.com/CRNX

SEE REVERSE FOR FULL AGENDA

Crinetics Pharmaceuticals, Inc.

Annual Meeting of Stockholders

THE BOARD OF DIRECTORS RECOMMENDS A VOTE:

FOR ON PROPOSALS 1 AND 2

PROPOSAL

- 1. To elect three directors to serve as Class I directors for a three-year term to expire at the 2025 annual meeting of stockholders.
 - 1.01 R. Scott Struthers, Ph.D.
 - 1.02 Matthew K. Fust
 - 1.03 Rogério Vivaldi Coelho, M.D.
- 2. To consider and vote upon the ratification of the appointment of BDO USA, LLP as our independent registered public accounting firm for the year ending December 31, 2022.
- 3. To transact such other business as may be properly brought before the meeting or any adjournment or postponement thereof.